MeiraGTx Acquires Rights to AAV-AQP1 Gene Therapy for Sjögren’s Syndrome
MeiraGTx recently acquired global rights over an investigational gene therapy called AAV-AQP1 being developed to treat the excessive dry mouth and eyes experienced by patients with Sjögren’s syndrome. The announcement comes after an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), an arm of the …